A post hoc analysis of Dupuytren contracture treated with collagenase Clostridium histolyticum across disease stages

Research output: Contribution to journalArticle


This post hoc analysis from a multicenter study (NCT01674634) was designed to evaluate the efficacy of collagenase Clostridium histolyticum (CCH) treatment in patients with different stages of Dupuytren contracture. Previously untreated patients who received two concurrent injections of CCH in two affected joints in the same finger were assessed by disease severity (Tubiana stage). The mean (SD) improvement in total fixed flexion contraction (FFC) 31 days post-CCH treatment in 181 patients was: 71.1 (36.5)% for Tubiana I, 77.0 (21.0)% for Tubiana II, 72.0 (20.4)% for Tubiana III and 66.4 (22.2)% for Tubiana IV. Treatment of metacarpophalangeal and proximal interphalangeal joints in the same finger resulted in a mean (SD) improvement of 82.5 (24.8)% and 66.4 (27.9)%, respectively. In conclusion, CCH is an effective treatment alternative for all stages of Dupuytren contracture and it provides a less invasive treatment alternative to surgery with similar short-term efficacy in patients with more severe disease.


External organisations
  • Drexel University
  • Swedish Orphan Biovitrum
  • Skåne University Hospital
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Surgery


  • Collagenase Clostridium histolyticum, Dupuytren contracture, fasciectomy, fixed flexion contracture, percutaneous needle fasciotomy
Original languageEnglish
Pages (from-to)301-306
JournalJournal of Plastic Surgery and Hand Surgery
Issue number5
Early online date2018 Jul 24
Publication statusPublished - 2018
Publication categoryResearch